Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial
العنوان: | Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial |
---|---|
المؤلفون: | Matthew J. Ellis, Manuela Rabaglio, JN Ingle, Judy-Anne W. Chapman, A. Le Maitre, GW Sledge, George Thomas Budd, Vered Stearns, Lois E. Shepherd, Cynthia X. Ma, Kathleen I. Pritchard, Paul E. Goss, Jessica Kundapur |
المصدر: | Journal of Clinical Oncology. 29:525-525 |
بيانات النشر: | American Society of Clinical Oncology (ASCO), 2011. |
سنة النشر: | 2011 |
مصطلحات موضوعية: | Gynecology, Oncology, Cancer Research, medicine.medical_specialty, Aromatase inhibitor, Vasomotor, medicine.drug_class, business.industry, medicine.medical_treatment, Cancer, Anastrozole, medicine.disease, Interim analysis, chemistry.chemical_compound, Exemestane, chemistry, Internal medicine, medicine, skin and connective tissue diseases, business, Adjuvant, Tamoxifen, medicine.drug |
الوصف: | 525 Background: New vasomotor or joint symptoms within 3 months of initiating either tamoxifen or anastrozole in the ATAC trial predicted superior recurrence-free survival (RFS). We hypothesized that women treated with anastrozole (A) or exemestane (E) in NCIC CTG Trial MA.27 who developed new or worsening vasomotor or joint symptoms would have improved RFS. There was no evidence of this correlation at the second interim analysis. We now report results by treatment arm from the final analysis. Methods: 7,576 ER+ postmenopausal women with early breast cancer were accrued to MA.27. Final analysis revealed no significant differences between A and E in the primary endpoints, event free or overall survival. We examined the effect of emergent vasomotor and joint symptoms 3 and 12 months following treatment initiation with A and E on subsequent RFS events excluding non-breast cancer deaths. We examined associations of symptoms with patient characteristics using chi-square tests, and associations of early symptom... |
تدمد: | 1527-7755 0732-183X |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::9abc5cef1f40ab04761bb167be062049Test https://doi.org/10.1200/jco.2011.29.15_suppl.525Test |
رقم الانضمام: | edsair.doi...........9abc5cef1f40ab04761bb167be062049 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 15277755 0732183X |
---|